Equillium
CompanyUnited States
Equillium develops one asset, in phase 1 (EQ504 in inflammatory diseases). Mostly peptide acting on inflammation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Multi-cytokine inhibitor targeting immunomodulatory pathways
Phase 1, Peptide, Inflammation, inflammatory diseases
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies6